Sana Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 29.00K shares, a 62.34% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 29.00K shares, a 94.46% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 302.00K shares, a 89.94% increase year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 76.00K shares, a 90.62% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 978.00K shares, a 62.83% decline from fiscal 2024.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 2.63M shares, a 129.58% increase from fiscal 2023.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 1.15M shares, a 7.91% increase from fiscal 2022.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 1.06M shares, a 33.04% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 29.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 436.00K shares derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 29.00K shares 10-Q · filed 2026-05-11 | 484.00K shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 302.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 978.00K shares 10-K · filed 2026-03-03 |
| 2025-09-30 | 76.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 835.00K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 77.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 1.57M shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 523.00K shares 10-Q · filed 2025-05-08 | 2.03M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 159.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | 2.63M shares 10-K · filed 2025-03-17 |
| 2024-09-30 | 810.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | 2.92M shares derived: sum of 4 quarters · filed 2024-11-08 |
| 2024-06-30 | 542.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 2.22M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 1.12M shares 10-Q · filed 2024-05-08 | 2.03M shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 453.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 1.15M shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 103.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 772.00K shares derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | 357.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 1.05M shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 233.00K shares 10-Q · filed 2023-05-08 | 1.01M shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 79.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 1.06M shares 10-K · filed 2023-03-16 |
| 2022-09-30 | 379.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | 1.45M shares derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | 320.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 1.77M shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 284.00K shares 10-Q · filed 2022-05-10 | 1.67M shares derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | 465.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | 1.59M shares 10-K · filed 2022-03-16 |
| 2021-09-30 | 704.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | |
| 2021-06-30 | 212.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | |
| 2021-03-31 | 205.00K shares 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |